Role of cytokines in GVL (ESb lymphoma) and GVHD after adoptive transfer of allogeneic T lymphocytes in mice.

ESb lymphoma cells injected i.v. into DBA/2 (H-2d) mice multiply rapidly in the liver and kill all mice in a few days. Adoptive transfer of allogeneic C57B1/6 (H-2b) tumor-immune or normal splenic lymphocytes to sublethally irradiated DBA/2 mice induced a marked antitumor state, graft-versus-leukemia (GVL), increasing the mean survival time 2-3-fold, but also induced an acute and lethal graft-versus host disease (GVHD). We have undertaken experiments to try to dissociate GVL from GVHD. Transfer of immune spleen cells induced a greater GVL than transfer of normal spleen cells with an equivalent to GVHD. Three to five million immune or normal CD8+ T lymphocytes were sufficient to induce both GVL and GVHD. Individual DBA/2 mice were labeled and followed. In mice undergoing GVHD, the spleens were repopulated by donor (H-2b) lymphocytes, and tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) were present in the sera of 26 of 27 and 18 of 20 mice, respectively, together with increased amounts of TNF-alpha and IL-6 mRNA in their spleens. This was in contrast to DBA/2 mice receiving allogeneic cells but not developing GVHD. Both interferon-alpha/beta (IFN-alpha/beta) and IL-12, which had proven very effective in association with adoptive transfer of syngeneic immune T lymphocytes in inhibiting ESb metastases, enhanced GVHD when administered with allogeneic immune or normal spleen cells, and >90% of mice died. Intensive IL-2 treatment inhibited GVHD while maintaining GVL.

[1]  直子 加藤,et al.  Graft-Versus-host Disease , 1999 .

[2]  A. Benner,et al.  Differences between graft-versus-leukemia and graft-versus-host reactivity. I. Interaction of donor immune T cells with tumor and/or host cells. , 1997, Blood.

[3]  J. Tschopp,et al.  Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease , 1996, The Journal of experimental medicine.

[4]  I. Gresser,et al.  Host CD4+ T Lymphocytes Are Required for the Synergistic Action of Interferon-α/β and Adoptively Transferred Immune Cells in the Inhibition of Visceral ESb Metastases , 1995 .

[5]  G. Szot,et al.  Interleukin-12 inhibits murine graft-versus-host disease. , 1995, Blood.

[6]  H. Hashimoto,et al.  Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease. , 1995, Journal of immunology.

[7]  F. Finkelman,et al.  IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. , 1994, Journal of immunology.

[8]  M. Imamura,et al.  Cytokines involved in graft-versus-host disease. , 1994, [Hokkaido igaku zasshi] The Hokkaido journal of medical science.

[9]  I. Gresser,et al.  Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN‐α/β , 1994 .

[10]  G. Szot,et al.  Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. , 1994, Blood.

[11]  J. Ferrara.  Cytokines other than growth factors in bone marrow transplantation. , 1994, Current opinion in oncology.

[12]  J. Antin.  Graft-versus-leukemia: no longer an epiphenomenon (editorial) , 1993 .

[13]  M. Sykes.  Novel approaches to the control of graft versus host disease. , 1993, Current opinion in immunology.

[14]  J. Ferrara,et al.  Cytokine dysregulation as a mechanism of graft versus host disease. , 1993, Current opinion in immunology.

[15]  C. Mathiot,et al.  Involvement of IFN-gamma and transforming growth factor-beta in graft-vs-host reaction-associated immunosuppression. , 1993, Journal of immunology.

[16]  C. Heusser,et al.  Detection of intracellular cytokines by flow cytometry. , 1993, Journal of immunological methods.

[17]  M. Sykes,et al.  IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. , 1993, Journal of immunology.

[18]  J. Ferrara,et al.  Cytokine dysregulation and acute graft-versus-host disease. , 1992, Blood.

[19]  P. Sehgal,et al.  THE RELATIONSHIP OF SERUM IL‐6 LEVELS TO ACUTE GRAFT‐VERSUS‐HOST DISEASE AND HEPATORENAL DISEASE AFTER HUMAN BONE MARROW TRANSPLANTATION , 1992, Transplantation.

[20]  P. Tiberghien,et al.  Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. , 1992, Blood.

[21]  R. Thompson,et al.  Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. , 1991, Blood.

[22]  F. Finkelman,et al.  Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody. , 1991, Journal of immunology.

[23]  M. Dallman,et al.  Analysis of cytokine gene expression during fetal thymic ontogeny using the polymerase chain reaction. , 1991, Journal of immunology.

[24]  D. Sachs,et al.  Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Sachs,et al.  In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment , 1990, The Journal of experimental medicine.

[26]  A. Mowat,et al.  Experimental studies of immunologically mediated enteropathy. V. Destructive enteropathy during an acute graft‐versus‐host reaction in adult BDF1 mice , 1990, Clinical and experimental immunology.

[27]  A. Mowat,et al.  Antibodies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. , 1989, Immunology.

[28]  P. Vassalli,et al.  Pneumopathies of the graft-versus-host reaction. Alveolitis associated with an increased level of tumor necrosis factor mRNA and chronic interstitial pneumonitis. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[29]  R. Schreiber,et al.  Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha. , 1989, Transplantation.

[30]  G. Klimpel,et al.  In vivo and in vitro production of IFN-beta and IFN-gamma during graft vs host disease. , 1988, Journal of immunology.

[31]  F. Belardelli,et al.  Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of friend erythroleukemia cells , 1988, International journal of cancer.

[32]  P. Vassalli,et al.  Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease , 1987, The Journal of experimental medicine.

[33]  H. Waldmann,et al.  The Depletion of T Cell Subsets in Vitro and in Vivo , 1986 .

[34]  J. Sprent,et al.  Surface markers of T cells causing lethal graft-vs-host disease to class I vs class II H-2 differences. , 1985, Journal of immunology.

[35]  D. Snover,et al.  A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. , 1985, Human pathology.

[36]  M. Stöhr,et al.  Suggestive evidence that the highly metastatic variant ESB of the T‐cell lymphoma eb is derived from spontaneous fusion with a host macrophage , 1984, International journal of cancer.

[37]  G. Santos,et al.  Sequential morphology of graft-versus-host disease in the rat radiation chimera☆ , 1982, Clinical Immunology and Immunopathology.

[38]  A. Rimm,et al.  Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity , 1979, Nature.

[39]  M. Lohmann‐Matthes,et al.  Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastasis formation in vivo , 1979, International journal of cancer.

[40]  M. Cheever,et al.  ADOPTIVE CHEMOIMMUNOTHERAPY OF CANCER IN ANIMALS: A REVIEW OF RESULTS, PRINCIPLES, AND PROBLEMS * , 1976, Annals of the New York Academy of Sciences.

[41]  A. Rimm,et al.  GRAFT VERSUS LEUKEMIA: III. Apparent Independent Antihost and Antileukemic Activity of Transplanted Immunocompetent Cells , 1973 .

[42]  A. Fefer.  Adoptive tumor immunotherapy in mice as an adjunct to whole-body x-irradiation and chemotherapy. A review. , 1973, Israel journal of medical sciences.

[43]  A. Fefer.  Immunotherapy of primary moloney sarcoma‐virus‐induced tumors , 1970, International journal of cancer.

[44]  G. Hale,et al.  What can be done to prevent graft versus host disease? , 1994, Current opinion in immunology.

[45]  D. Wall,et al.  The role of tumor necrosis factor and interferon gamma in graft-versus-host disease and related immunodeficiency. , 1994, Transplantation.

[46]  M. Sykes.  Dissociating graft-vs-host disease from the graft-vs-leukemia effect of allogeneic T cells: the potential role of IL-2. , 1992, Bone marrow transplantation.

[47]  Slavin Re,et al.  The pathology of bone marrow transplantation. , 1974 .

[48]  M. Bortin.  GRAFT-VERSUS-LEUKEMIA , 1974 .